Accordingly, peak levels of C-reactive protein (CRP) in the early toxic phase after HSCT are associated with treatment-related complications, such as mucositis, acute graft-vs.-host disease (aGvHD), vascular endothelial syndromes including sinusoidal obstruction syndrome, and severe infections, and are predictive of treatment-related mortality (TRM) (4, 5, 7, 8). The gene discussed is CRP; the disease is hepatic veno-occlusive disease.